Top

Published in:

01-01-2015 | Original Article

Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy

Authors: Daniel S. Oh, Bridget Koontz, Stephen J. Freedland, Leah Gerber, Pretesh Patel, Stephen Lewis, David S. Yoo, James Oleson, Joseph K. Salama

Published in: World Journal of Urology | Issue 1/2015

Abstract

Purpose/objective(s)

Recent in vitro and in vivo evidence has suggested that statin medications may have anticancer activity. We sought to determine whether statin use was associated with improved clinical outcome in men treated with brachytherapy for prostate cancer.

Materials/methods

A database of men with prostate cancer treated with permanent Iodine-125 brachytherapy between January 1999 and February 2009 was retrospectively analyzed. Standard guidelines (i.e., American Brachytherapy Society selection criteria) were used for selecting patients for brachytherapy. Biochemical failure was defined using the Phoenix definition.

Results

From a total of 247 men with prostate adenocarcinoma treated with brachytherapy, 174 patients (70 %) were identified as using statin medications, either during initial visit or during follow-up. Median PSA follow-up was 51 months after date of implant (range 9.4–140.35). Overall biochemical failure rate was 7.3 % (18 patients). On univariate analysis, statin use was associated with significantly improved freedom from biochemical failure [hazard ratio (HR) 0.28; 95 % CI 0.10–0.72; p < 0.01 by log-rank test]. In multivariate Cox analysis performed with the variables statin use, pretreatment PSA, clinical T stage, Gleason score, and D90 or V100, statin use remained significantly associated with improved freedom from biochemical failure (HR 0.288; 95 % CI 0.086–0.886; p = 0.0299).

Conclusions

Statin use was associated with a significant improvement in freedom from biochemical failure in this cohort of men treated with brachytherapy for prostate cancer. Further investigation into the favorable effect of statin use on brachytherapy and radiation therapy in general is warranted, including prospective trials.

Platz EA et al (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24):1819–1825PubMedCrossRef

Murtola TJ et al (2007) Cholesterol-lowering drugs and prostate cancer risk: a population-based case–control study. Cancer Epidemiol Biomark Prev 16(11):2226–2232CrossRef

Poynter JN et al (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184–2192PubMedCrossRef

Nielsen SF, Nordestgaard BG, Bojesen SE (2012) Statin use and reduced cancer-related mortality. N Engl J Med 367(19):1792–1802PubMedCrossRef

Hamilton RJ et al (2010) Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 116(14):3389–3398PubMedCentralPubMedCrossRef

Ku JH et al (2011) Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 14(1):63–68PubMedCrossRef

Kollmeier MA et al (2011) Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 79(3):713–718PubMedCrossRef

Gutt R et al (2010) Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 28(16):2653–2659PubMedCrossRef

Soto DE et al (2009) No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer. Urology 73(1):158–162PubMedCrossRef

10.

Moyad MA et al (2005) Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer. Urology 66(6):1150–1154PubMedCrossRef

11.

Graaf MR et al (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30(7):609–641PubMedCrossRef

12.

DeClue JE et al (1991) Inhibition of cell growth by lovastatin is independent of ras function. Cancer Res 51(2):712–717PubMed

13.

Feleszko W et al (1999) Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81(4):560–567PubMedCrossRef

14.

Matar P et al (1999) Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastas 17(1):19–25CrossRef

15.

Kusama T et al (2002) 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122(2):308–317PubMedCrossRef

16.

Zhuang L et al (2005) Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 115(4):959–968PubMedCentralPubMedCrossRef

17.

Rosenthal SA et al (2011) American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 79(2):335–341PubMedCrossRef

18.

Scardino P (2005) Update: NCCN prostate cancer clinical practice guidelines. J Natl Compr Cancer Netw 3(Suppl 1):S29–S33

19.

Roach M 3rd et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974PubMedCrossRef

20.

Moyad MA et al (2006) Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 26(4):298–303PubMed

21.

Hamilton RJ et al (2008) The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 100(21):1511–1518PubMedCrossRef

22.

Papagikos MA et al (2005) Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? Brachytherapy 4(4):252–258PubMedCrossRef

23.

Kollmeier MA, Stock RG, Stone N (2003) Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57(3):645–653PubMedCrossRef

Title: Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy
Authors: Daniel S. Oh
Bridget Koontz
Stephen J. Freedland
Leah Gerber
Pretesh Patel
Stephen Lewis
David S. Yoo
James Oleson
Joseph K. Salama
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2015
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-014-1281-x

At a glance: The STEP trials

Springer Medicine

Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy

Abstract

Purpose/objective(s)

Materials/methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose/objective(s)

Materials/methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Predictive role of tissue-based molecular markers in patients treated with sunitinib for metastatic renal cell carcinoma

Feasibility and outcomes regarding open and laparoscopic radical prostatectomy in patients with previous synthetic mesh inguinal hernia repair: meta-analysis and systematic review of 7,497 patients

An update on metabolic assessment in patients with urinary lithiasis

The use of partial nephrectomy: results from a contemporary national prospective multicenter study

Matched pair analysis of laparoscopic versus open radical nephrectomy for the treatment of T3 renal cell carcinoma

Sexual quality of life after total phalloplasty in men with penile deficiency: an exploratory study